<DOC>
	<DOCNO>NCT03093389</DOCNO>
	<brief_summary>To investigate tolerability safety four multiple-dose regimen BIA 6-512 ( 25 mg , 50 mg , 100 mg , 150 mg 6 time daily ) healthy volunteer characterise steady-state pharmacokinetic profile BIA 6-512 ( 25 mg , 50 mg , 100 mg , 150 mg 6 time daily ) healthy volunteer .</brief_summary>
	<brief_title>Tolerability Steady-state Pharmacokinetics BIA 6-512</brief_title>
	<detailed_description>Single-centre , double-blind , randomised , placebo-controlled study four multiple-rising dos four sequential group 10 healthy volunteer . Eligible subject admit UFH day ( Day 0 ) prior receive first dose study medication . On morning next day ( Day 1 ) , subject start receive BIA 6-512/Placebo 4 h interval ( 6 times/day ) 48 h ( 13 investigational product administration , total ) . Subjects remain confined UFH admission ( Day 0 ) least 24 h post last dose ( Day 4 ) ; , discharge request return follow-up visit . At give time-points , subject submit vital sign record , brief neurological examination , 12-lead ECG . Blood sample plasma drug assay take follow time : Dose 1 : pre-dose ¼ , ½ , ¾ , 1 , 1½ , 2 , 3 hour post-dose ; Doses 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 : pre-dose ; Dose 13 : pre-dose ¼ , ½ , ¾ , 1 , 1½ , 2 , 3 , 4 , 6 , 8 , 12 , 16 24 hour post-dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects clinical laboratory test result clinically acceptable screen admission . Subjects negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen . Subjects negative screen alcohol drug abuse screen admission . Subjects nonsmoker smoke ≤ 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative urine pregnancy test screen admission . Subjects conform inclusion criterion , Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant drug food hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen admission . Subjects acute gastrointestinal symptom time screen admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use medicine within 2 week first admission , opinion investigator , may affect safety study assessment . Subjects use investigational drug participate clinical trial within 2 month admission . Subjects donate received blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method ( doublebarrier , intrauterine device abstinence ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>